22 results for author:"Kefford R.F." in Literature citations
Results Customize
› Repeat search in UniProtKB (8)
| Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Long G.V., Wilmott J.S., Capper D., Preusser M., Zhang Y.E., Thompson J.F., Kefford R.F., von Deimling A., Scolyer R.A. Am. J. Surg. Pathol. 37:61-65(2013) · Mapped (3) |
| Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Shi H., Moriceau G., Kong X., Koya R.C., Nazarian R., Pupo G.M., Bacchiocchi A., Dahlman K.B., Chmielowski B., Sosman J.A. et al. Cancer Discov 2:414-424(2012) · Mapped (3) |
| Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Menzies A.M., Haydu L.E., Visintin L., Carlino M.S., Howle J.R., Thompson J.F., Kefford R.F., Scolyer R.A., Long G.V. Clin. Cancer Res. 18:3242-3249(2012) · Mapped (3) |
| Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Shi H., Moriceau G., Kong X., Lee M.K., Lee H., Koya R.C., Ng C., Chodon T., Scolyer R.A., Dahlman K.B. et al. Nat Commun 3:724-724(2012) · Mapped (3) |
| MC1R genotypes and risk of melanoma before age 40 years: a population-based case-control-family study. Cust A.E., Goumas C., Holland E.A., Agha-Hamilton C., Aitken J.F., Armstrong B.K., Giles G.G., Kefford R.F., Schmid H., Hopper J.L. et al. Int. J. Cancer 131:E269-81(2012) · Mapped (21) |
| A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Yokoyama S., Woods S.L., Boyle G.M., Aoude L.G., MacGregor S., Zismann V., Gartside M., Cust A.E., Haq R., Harland M. et al. |
| Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Long G.V., Menzies A.M., Nagrial A.M., Haydu L.E., Hamilton A.L., Mann G.J., Hughes T.M., Thompson J.F., Scolyer R.A., Kefford R.F. J. Clin. Oncol. 29:1239-1246(2011) · Mapped (3) |
| IGFBP7 is not required for B-RAF-induced melanocyte senescence. Scurr L.L., Pupo G.M., Becker T.M., Lai K., Schrama D., Haferkamp S., Irvine M., Scolyer R.A., Mann G.J., Becker J.C. et al. Cell 141:717-727(2010) · Mapped (4) |
| Oncogenic B-RAF(V600E) promotes anchorage-independent survival of human melanocytes. Becker T.M., Philipsz S., Scurr L.L., Fung C., Haferkamp S., Kefford R.F., Rizos H. J. Invest. Dermatol. 130:2144-2147(2010) · Mapped (3) |
| The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Haferkamp S., Tran S.L., Becker T.M., Scurr L.L., Kefford R.F., Rizos H. Aging (Albany NY) 1:542-556(2009) · Mapped (32) |
| Genome-wide association study identifies three loci associated with melanoma risk. Bishop D.T., Demenais F., Iles M.M., Harland M., Taylor J.C., Corda E., Randerson-Moor J., Aitken J.F., Avril M.F., Azizi E. et al. Nat. Genet. 41:920-925(2009) · Mapped (32) |
| The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Becker T.M., Haferkamp S., Dijkstra M.K., Scurr L.L., Frausto M., Diefenbach E., Scolyer R.A., Reisman D.N., Mann G.J., Kefford R.F. et al. Mol. Cancer 8:4-4(2009) · Mapped (9) |
| p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism. Rizos H., Scurr L.L., Irvine M., Alling N.J., Kefford R.F. Cell Cycle 6:1741-1747(2007) · Mapped (59) |
| Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations. Becker T.M., Rizos H., de la Pena A., Leclercq I.A., Woodruff S., Kefford R.F., Mann G.J. Biochem. Biophys. Res. Commun. 332:873-879(2005) · Mapped (6) |
| p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. Rizos H., Woodruff S., Kefford R.F. |
| Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis. Gallagher S., Kefford R.F., Rizos H. Cell Cycle 4:465-472(2005) · Mapped (32) |
| Association of p14ARF with the p120E4F transcriptional repressor enhances cell cycle inhibition. Rizos H., Diefenbach E., Badhwar P., Woodruff S., Becker T.M., Rooney R.J., Kefford R.F. J. Biol. Chem. 278:4981-4989(2003) · UniProtKB (2) · Mapped (3) |
| Differential expression of a novel gene, WDNM1, in nonmetastatic rat mammary adenocarcinoma cells. Dear T.N., Ramshaw I.A., Kefford R.F. |
| Transcriptional down-regulation of a rat gene, WDNM2, in metastatic DMBA-8 cells. Dear T.N., McDonald D.A., Kefford R.F. Cancer Res. 49:5323-5328(1989) · UniProtKB (1) |
| The WDNM1 gene product is a novel member of the 'four-disulphide core' family of proteins. Dear T.N., Kefford R.F. Biochem. Biophys. Res. Commun. 176:247-254(1991) · UniProtKB (1) · Mapped (1) |
| Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. Henderson B.R., Tansey W.P., Phillips S.M., Ramshaw I.A., Kefford R.F. |
| Loss of keratin expression in anaplastic carcinoma cells due to posttranscriptional down-regulation acting in trans. Paine M.L., Gibbins J.R., Chew K.E., Demetriou A., Kefford R.F. |